Related Experiment Video

Updated: May 5, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

HLA-DM gene polymorphisms in atopic dermatitis

S Kuwata1, M Yanagisawa, H Nakagawa

  • 1Department of Transfusion Medicine and Immunohematology, Faculty of Medicine, University of Tokyo, Japan.

The Journal of Allergy and Clinical Immunology
|December 1, 1996
PubMed

Insights

Human Leukocyte Antigen (HLA)-DM gene polymorphisms were studied in Japanese atopic dermatitis patients. The study found no significant association, suggesting HLA-DM genes are not primary contributors to atopic dermatitis susceptibility.

Area of Science:

  • Immunogenetics
  • Molecular Biology
  • Dermatology

Background:

  • Human Leukocyte Antigen (HLA)-DM molecules play a crucial role in antigen presentation for HLA class II-restricted immune responses.
  • Atopic dermatitis is a complex inflammatory skin disease with a suspected genetic component within the HLA class II region.

Purpose of the Study:

  • To investigate the association between polymorphisms in Human Leukocyte Antigen (HLA)-DM genes (DMA and DMB) and the pathogenesis of atopic dermatitis in a Japanese population.
  • To determine if specific HLA-DM alleles or haplotypes contribute to atopic dermatitis susceptibility.

Main Methods:

  • Genomic DNA was extracted from 37 Japanese patients with atopic dermatitis and 52 healthy controls.
  • Polymerase chain reaction (PCR) amplification of polymorphic exons of DMA and DMB genes was performed.
  • PCR products were analyzed using restriction fragment length polymorphism (RFLP) with specific restriction endonucleases (FokI, HinfI, AciI, SfaNI for DMA; HhaI, BsrI, ApaLI, Bsp1286I for DMB) to identify HLA-DM alleles.

Main Results:

  • Three DMA alleles and three DMB alleles were identified in the study cohort.
  • No significant increase or association was found for any specific DMA or DMB alleles in atopic dermatitis patients compared to controls.
  • One patient carried the rare DMA*0103 allele, previously reported in Caucasian populations.
  • The DMA*0102 allele was found to form a haplotype with DRB1*1201/DQB1*0301 and DRB1*0901/DQB1*0301 in the Japanese population.

Conclusions:

  • The study concludes that Human Leukocyte Antigen (HLA)-DM gene polymorphisms are unlikely to be a primary factor in the susceptibility to atopic dermatitis.
  • Further research into the functional significance of HLA-DM gene variations may offer insights into HLA class II-associated diseases.

More Related Videos

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

9.8K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

5.7K

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.7K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
209
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
359